Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ascentage Oncology Drug Effective in Preclinical Tests for COVID Cytokine Storm

publication date: May 19, 2022

Shanghai Ascentage Pharma reported that olverembatinib effectively inhibited cytokine release storm in a preclinical test of the SARS-CoV-2 omicron variant. The study was conducted by researchers from Fred Hutchinson Cancer Research Center in Seattle. Olverembatinib is already approved in China for two forms of chronic myeloid leukemia. Although most COVID-19 patients develop only mild to moderate symptoms, 15-20% of them face the hyper-inflammation induced by a cytokine storm, which leads to respiratory failure. Ascentage said it anticipates follow-up studies of olverembatinib in patients with severe cases of COVID-19. More details....

Stock Symbols: (HK: 6855)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here